Tobin C. Schilke
2021 - Revance Therapeutics
Compensation breakdown
| Non-Equity Incentive Plan | $192,336 |
|---|---|
| Option Awards | $634,014 |
| Salary | $429,802 |
| Stock Awards | $1,267,172 |
| Other | $11,470 |
| Total | $2,534,794 |
Schilke received $1.3M in stock awards, accounting for 50% of the total pay in 2021.
Schilke also received $192.3K in non-equity incentive plan, $634K in option awards, $429.8K in salary and $11.5K in other compensation.
Rankings
In 2021, Tobin C. Schilke's compensation ranked 5,091st out of 12,397 executives tracked by ExecPay. In other words, Schilke earned more than 58.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,091 out of 12,397 | 59th |
Division Manufacturing | 2,140 out of 5,492 | 61st |
Major group Chemicals And Allied Products | 917 out of 2,367 | 61st |
Industry group Drugs | 820 out of 2,090 | 61st |
Industry Pharmaceutical Preparations | 585 out of 1,537 | 62nd |
Pay ratio
| Tobin C. Schilke's Pay | $2,534,794 |
|---|---|
| Median Employee's Pay | $248,326 |
| Pay Ratio | 10to 1 |
In 2021, the annual total compensation of Tobin C. Schilke was $2,534,794.
The annual total compensation of the median employee at Revance Therapeutics was $248,326.
The ratio of Tobin C. Schilke's pay to the pay of median employee was therefore 10 to one.
Schilke's colleagues
We found four more compensation records of executives who worked with Tobin C. Schilke at Revance Therapeutics in 2021.
News
March 24, 2022
March 11, 2021
March 26, 2020
March 25, 2019